All In Biotech

NDA 212161 · Foldrx Pharms

Vyndamax

Tafamidis · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Oct 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

May 3, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

37

7 Phase 3, 2 recruiting

FAERS reports

12,176

9,441 serious, 4,214 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2026.

1. INDICATIONS AND USAGE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )

Mechanism: Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 3, 2019 Original approval · Type 2 - New Active Ingredient OrphanLabelLetterReview
1 products under this application
  • VYNDAMAX · TAFAMIDIS 61MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tafamidis" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3,266
  • dyspnoea804
  • off label use661
  • cardiac failure638
  • fatigue585
  • fall479
  • atrial fibrillation397
  • dizziness357
  • malaise349
  • asthenia332
  • condition aggravated311
  • cardiac failure congestive308

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20153
20161
20171
20184
2019123
2020644
20211,043
20221,755
20232,500
20242,545
20252,110
20261,447

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vyndamax (Tafamidis)

2024 spending

$2.83B

Beneficiaries

13,925

109,373 claims

Per beneficiary

$203,290

$743.93 per unit

View as table
YearSpending
2020$253,267,541
2021$532,147,190
2022$845,100,487
2023$1,349,659,508
2024$2,830,811,857

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 66 on PubMed

Sponsor: Foldrx Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.